Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Mugs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by themagicboxon Nov 18, 2021 1:39pm
233 Views
Post# 34141787

RE:RE:Mugs

RE:RE:MugsThe interview was recorded, so itll be posted on Radius Research's youtube channel either later today or tomorrow. https://www.youtube.com/c/radiusresearch

the main takeaway as far as SP movement is concerend wont happen till mid next year when they expect to enter ph2 of this acute pain indication. He acknowledge that many investors are waiting for more concrete data and plans before re-entering

from a drug deveolpment perspective, it seems that the current hypothesis for the liver enzyme elevation is that the exogenous H2S from H2S moiety is inhibiting endogenous H2S. So the body isnt able to generate its own H2S as before. Consequently contributing to liver enzyme issue.

While this isnt an issue at all for the acute indication (which is a 14 day regimen) its a problem for the chronic indication. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities